Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1997 1
1999 1
2000 2
2002 2
2003 5
2004 2
2006 2
2007 1
2011 1
2012 2
2013 1
2014 5
2015 3
2016 2
2017 1
2018 2
2019 2
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

37 results
Results by year
Filters applied: . Clear all
Page 1
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M. Cortes JE, et al. Among authors: laird ad. Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16. Leukemia. 2019. PMID: 30555165 Free PMC article. Clinical Trial.
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH. Yakes FM, et al. Among authors: laird ad. Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16. Mol Cancer Ther. 2011. PMID: 21926191 Free article.
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E, Gökbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H. Jabbour E, et al. Among authors: laird ad. Leuk Res. 2020 Jan;88:106283. doi: 10.1016/j.leukres.2019.106283. Epub 2019 Nov 25. Leuk Res. 2020. PMID: 31790983 Free article. Clinical Trial.
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. Mendel DB, et al. Among authors: laird ad. Clin Cancer Res. 2003 Jan;9(1):327-37. Clin Cancer Res. 2003. PMID: 12538485 Free article.
Oncoprotein signalling and mitosis.
Laird AD, Shalloway D. Laird AD, et al. Cell Signal. 1997 May-Jun;9(3-4):249-55. doi: 10.1016/s0898-6568(96)00176-3. Cell Signal. 1997. PMID: 9218124 Review.
Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.
Rice KD, Kim MH, Bussenius J, Anand NK, Blazey CM, Bowles OJ, Canne-Bannen L, Chan DS, Chen B, Co EW, Costanzo S, DeFina SC, Dubenko L, Engst S, Franzini M, Huang P, Jammalamadaka V, Khoury RG, Klein RR, Laird AD, Le DT, Mac MB, Matthews DJ, Markby D, Miller N, Nuss JM, Parks JJ, Tsang TH, Tsuhako AL, Wang Y, Xu W. Rice KD, et al. Among authors: laird ad. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2693-7. doi: 10.1016/j.bmcl.2012.03.011. Epub 2012 Mar 10. Bioorg Med Chem Lett. 2012. PMID: 22450127
37 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page